Bristol Myers announces that KRAZATI (adagrasib) in combination with cetuximab demonstrates clinically meaningful activity as a targeted treatment option for patients with previously treated locally advanced or metastatic KRAS G12C-mutated colorectal cancer (CRC).

The latest data were presented in an oral presentation at the annual meeting of the American Association for Cancer Research (AACR).

KRASG12C mutations act as oncogenic drivers and occur in around 3-4% of colorectal cancers. In previous studies, cetuximab monotherapy offered no clinical benefit in patients with KRAS-mutated colorectal cancer.

' Patients with KRASG12C-mutated colorectal cancer have always faced poor prognoses and still need additional treatment options,' said Scott Kopetz, M.D., Ph.D, FACP, associate vice president for translational research and professor in the Department of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center.

' Although KRAS has previously been considered 'non-drugable', these data from KRYSTAL-1 reinforce the potential benefit of adagrasib for these specific patients. '

' While there have been advances in the treatment of colorectal cancer, there remain groups of patients, such as those with KRAS-mutated cancers, who continue to require new targeted treatment options, ' said Anne Kerber, Senior Vice President, Head of Late Stage Clinical Development, Hematology, Oncology, Cellular Therapy (HOCT) at Bristol Myers Squibb. ' These data underscore the importance of screening and identifying KRASG12C mutations in CRC patients. '

Copyright (c) 2024 All rights reserved.